Z11.52 — Encounter for screening for COVID-19
ICD-10-CM
Prior Authorization
No Prior Auth Required
No active coverage policies found for this code (low confidence)
Documentation Required
- No explicit documentation requirements are stated in this Clinical Policy Bulletin.
- Claims must demonstrate that selection criteria are met for covered CPT codes (e.g., 91065 and 95012) — supporting clinical records, history, and relevant prior conservative treatment (such as the 2-week lactose‑free diet for HBT)
- When a test is billed, the medical record should support the specific covered indication listed in the policy (e.g., lactose intolerance symptoms after dietary trial, or asthma evaluation/monitoring) and include relevant clinical notes, prior treatment documentation, diagnosis codes, and age where applicable
- For studies of OSA biomarkers: OSA diagnosis confirmed with a full overnight or home-based PSG (polysomnography) was required in retained studies (Canto Gde et al 2015).
Key Coverage Criteria
- None specified. Aetna considers the analysis of volatile organic compounds experimental and investigational for the indications listed below (see Limitations).
- Measurement of exhaled nitric oxide (FeNO) for evaluation of asthma
- Hydrogen breath testing (HBT) for evaluation of suspected lactose intolerance/deficiency after a 2-week trial of a lactose-free diet and symptoms of lactose intolerance persist
- Measurement of exhaled nitric oxide (FeNO) for monitoring response to long-term control therapy in members aged 5 years and older
- CPT 91065 (Breath hydrogen or methane test) covered when selection criteria are met
- CPT 95012 (Nitric oxide expired gas determination) covered when selection criteria are met
3 Active Policies
CIGNA-0557 — COVID-19: In Vitro Diagnostic Testing - (0557)
AETNA-CPB-0691 — Exhaled Breath Tests
AETNA-CPB-0717 — Analysis of Volatile Organic Compounds
Related Codes
Have a follow-up question?
Ask Verity about documentation requirements, denial risks, or coverage in your state.